Search results
Your search for ���������������,���������������������������������������:kn39��� returned no results
Showing 151 to 165 of 814 results for ���������������,���������������������������������������:know���
Showing 151 to 165 of 814 results for ���������������,���������������������������������������:know���
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
it should be documented very clearly, for other healthcare team members to know what discussion has been held. There is a need to...
This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.
A selection of resources to help you deliver high-quality care and services using NICE guidance
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Improving quality of care in residential care and nursing homes
people`s expectations were raised with regards to the care of older people. We know that many people on the Island are very tolerant and...
Find out about the progress made by the health and care system in implementing NICE guidance on children and young people's healthcare
This quality standard covers oral health, including dental health and daily mouth care, for adults in care homes (with and without nursing provision). It describes high-quality care in priority areas for improvement.
How NICE uses cookies and how you can manage them.
want to learn, I just did not think I was worth bothering about. But now I know I am. Abuse can make you feel helpless and as though you...
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS175Show all sections
Sections for QS175
- Quality statements
- Quality statement 1: Early assessment and treatment
- Quality statement 2: Discussion about psychological treatment options
- Quality statement 3: First-line psychological treatment for binge eating disorder
- Quality statement 4: Bulimia-nervosa-focused family therapy
- Quality statement 5: Coordinated care across services
- Quality statement 6: Risk assessment when moving between services
- About this quality standard
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.